

Generalized Myasthenia Gravis (gMG) Symptom Assessment

The **Myasthenia Gravis Activities of Daily Living (MG-ADL)** scale assesses the impact of gMG on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

Track your symptoms regularly. If you track them weekly, try to do it at the same time each week for consistency.

Date: _____ **Time:** _____ AM PM **Week:** _____

Grade	0	1	2	3	Score (0, 1, 2, or 3)
1. Talking	Normal	Intermittent slurring or nasal speech	Constant slurring or nasal, but can be understood	Difficult to understand speech	+
2. Chewing	Normal	Fatigue with solid food	Fatigue with soft food	Gastric tube	+
3. Swallowing	Normal	Rare episode of choking	Frequent choking necessitating changes in diet	Gastric tube	+
4. Breathing	Normal	Shortness of breath with exertion	Shortness of breath at rest	Ventilator dependence	+
5. Impairment of ability to brush teeth or comb hair	None	Extra effort, but no rest periods needed	Rest periods needed	Cannot do one of these functions	+
6. Impairment of ability to arise from a chair	None	Mild, sometimes uses arms	Moderate, always uses arms	Severe, requires assistance	+
7. Double vision	None	Occurs, but not daily	Daily, but not constant	Constant	+
8. Eyelid droop	None	Occurs, but not daily	Daily, but not constant	Constant	+

MG-ADL score total =
Add lines 1-8

This information has been provided for educational purposes only and is not meant to be a substitute for professional medical advice. Patients should not use this information for diagnosing a health condition. Patients should always consult a healthcare professional for medical advice or information about diagnosis and treatment.

Source: Wolfe GI, et al. *Neurology*. 1999;52(7):1487-1489.

➔ My other generalized myasthenia gravis symptoms

➔ Questions for my neurologist

➔ Other notes

Remember to let your neurologist know if there are any changes to your MG-ADL score or if you have questions about VYVGART for IV infusion or VYVGART Hytrulo for subcutaneous injection.

**For other questions, a Nurse Case Manager is ready to help you.
Give them a call at: 1-833-MY-PATH-1 (1-833-697-2841)**

MG-ADL=Myasthenia Gravis Activities of Daily Living; IV=intravenous
Visit VYVGART.com/glossary for a glossary of terms.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

**ASK YOUR
DOCTOR
TO SIGN YOU UP**



With My VYVGART Path, a Nurse Case Manager is waiting to help you through your VYVGART treatment journey.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

- **Infection.** VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART or VYVGART HYTRULO. Tell your healthcare provider if you have any history of infections. Tell your healthcare provider right away if you have signs or symptoms of an infection during treatment with VYVGART or VYVGART HYTRULO such as fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. If a serious infection occurs, your doctor will treat your infection and may even stop your VYVGART or VYVGART HYTRULO treatment until the infection has resolved.
- **Undesirable immune reactions (hypersensitivity reactions).** VYVGART and VYVGART HYTRULO can cause the immune system to have undesirable reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. In clinical studies, the reactions were mild or moderate and occurred within 1 hour to 3 weeks of administration, and the reactions did not lead to treatment discontinuation. Your healthcare provider should monitor you during and after treatment and discontinue VYVGART or VYVGART HYTRULO if needed. Tell your healthcare provider immediately about any undesirable reactions to VYVGART or VYVGART HYTRULO.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

- Have a history of infection or you think you have an infection.
- Have received or are scheduled to receive a vaccine (immunization). Discuss with your healthcare provider whether you need to receive age-appropriate immunizations before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO. The use of vaccines during treatment with VYVGART or VYVGART HYTRULO has not been studied, and the safety with live or live-attenuated vaccines is unknown. Administration of live or live-attenuated vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO.
- Are pregnant or plan to become pregnant and are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects of efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART for IV infusion and what is VYVGART HYTRULO for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for [VYVGART](#) and the full Prescribing Information for [VYVGART HYTRULO](#), and talk to your doctor.

VYVGART[®]
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

VYVGART[®] Hytrulo
(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial